<div class="article-table-content" id="dme13817-tbl-0001">
               <header class="article-table-caption"><span class="table-caption__label">Table 1.
            </span>Baseline characteristics according to baseline diabetes status in the pool of 14 phase 2/3 trials (safety population)
               </header><div class="article-table-content-wrapper">
                  <table class="table article-section__table">
<thead>
<tr>
<th class="right-bordered-cell left-aligned"></th>
                           
                           <th colspan="2" class="bottom-bordered-cell center-aligned">People with diabetes <i>N</i> = 1554
                           </th>
                           
                           <th colspan="2" class="bottom-bordered-cell center-aligned">People without diabetes <i>N</i> = 3680
                           </th>
                           
                        </tr>
<tr>
<th class="bottom-bordered-cell right-bordered-cell left-aligned"></th>
                           
                           <th class="bottom-bordered-cell center-aligned">Control <i>n</i> = 558
                           </th>
                           
                           <th class="bottom-bordered-cell center-aligned">Alirocumab <i>n</i> = 996
                           </th>
                           
                           <th class="bottom-bordered-cell center-aligned">Control <i>n</i> = 1336
                           </th>
                           
                           <th class="bottom-bordered-cell center-aligned">Alirocumab <i>n</i> = 2344
                           </th>
                           
                        </tr>
</thead>
<tbody>
<tr>
<td class="right-bordered-cell left-aligned">Age, years</td>
                           
                           <td class="center-aligned">61.7 (9.6)</td>
                           
                           <td class="center-aligned">62.1 (9.5)</td>
                           
                           <td class="center-aligned">58.9 (11.2)</td>
                           
                           <td class="center-aligned">58.3 (11.6)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Male, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">313 (56.1)</td>
                           
                           <td class="center-aligned">587 (58.9)</td>
                           
                           <td class="center-aligned">837 (62.6)</td>
                           
                           <td class="center-aligned">1476 (63.0)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">BMI, kg/m<sup>2</sup>
</td>
                           
                           <td class="center-aligned">32.8 (6.0)</td>
                           
                           <td class="center-aligned">32.3 (6.4)</td>
                           
                           <td class="center-aligned">29.0 (5.0)</td>
                           
                           <td class="center-aligned">29.0 (5.1)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Atherosclerotic cardiovascular disease<a class="noteLink scrollableLink" title="Link to note" id="dme13817-note-0004_23-controller" href="#dme13817-note-0004_23" aria-controls="dme13817-note-0004_23" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">*</a><div class="footNotePopup" id="dme13817-note-0004_23" aria-labelledby="dme13817-note-0004_23-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span>
                                    *Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. <sup>†</sup><i>n</i>/<i>N</i> = number of people in phase 3 studies only. <sup>‡</sup>High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
                                    <br></span><span class="chevronDown"></span>
</div>, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">346 (62.0)</td>
                           
                           <td class="center-aligned">637 (64.0)</td>
                           
                           <td class="center-aligned">912 (68.3)</td>
                           
                           <td class="center-aligned">1640 (70.0)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Chronic kidney disease<a class="noteLink scrollableLink" title="Link to note" id="dme13817-note-0004_24-controller" href="#dme13817-note-0004_24" aria-controls="dme13817-note-0004_24" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">†</a><div class="footNotePopup" id="dme13817-note-0004_24" aria-labelledby="dme13817-note-0004_24-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span>
                                    *Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. <sup>†</sup><i>n</i>/<i>N</i> = number of people in phase 3 studies only. <sup>‡</sup>High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
                                    <br></span><span class="chevronDown"></span>
</div>, <i>n</i>/<i>N</i> (%)
                           </td>
                           
                           <td class="center-aligned">79/546 (14.5)</td>
                           
                           <td class="center-aligned">149/979 (15.2)</td>
                           
                           <td class="center-aligned">80/1246 (6.4)</td>
                           
                           <td class="center-aligned">170/2203 (7.7)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Heterozygous familial hypercholesterolemia<a class="noteLink scrollableLink" title="Link to note" id="dme13817-note-0004_25-controller" href="#dme13817-note-0004_25" aria-controls="dme13817-note-0004_25" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">†</a><div class="footNotePopup" id="dme13817-note-0004_25" aria-labelledby="dme13817-note-0004_25-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span>
                                    *Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. <sup>†</sup><i>n</i>/<i>N</i> = number of people in phase 3 studies only. <sup>‡</sup>High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
                                    <br></span><span class="chevronDown"></span>
</div>, <i>n</i>/<i>N</i> (%)
                           </td>
                           
                           <td class="center-aligned">57/546 (10.4)</td>
                           
                           <td class="center-aligned">90/979 (9.2)</td>
                           
                           <td class="center-aligned">404/1246 (32.4)</td>
                           
                           <td class="center-aligned">787/2203 (35.7)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Hypertension, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">492 (88.2)</td>
                           
                           <td class="center-aligned">887 (89.1)</td>
                           
                           <td class="center-aligned">766 (57.3)</td>
                           
                           <td class="center-aligned">1324 (56.5)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Statins, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">524 (93.9)</td>
                           
                           <td class="center-aligned">941 (94.5)</td>
                           
                           <td class="center-aligned">1117 (83.6)</td>
                           
                           <td class="center-aligned">2079 (88.7)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">High‐intensity statins<a class="noteLink scrollableLink" title="Link to note" id="dme13817-note-0004_26-controller" href="#dme13817-note-0004_26" aria-controls="dme13817-note-0004_26" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">‡</a><div class="footNotePopup" id="dme13817-note-0004_26" aria-labelledby="dme13817-note-0004_26-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span>
                                    *Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. <sup>†</sup><i>n</i>/<i>N</i> = number of people in phase 3 studies only. <sup>‡</sup>High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
                                    <br></span><span class="chevronDown"></span>
</div>, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">239 (45.7)</td>
                           
                           <td class="center-aligned">451 (47.9)</td>
                           
                           <td class="center-aligned">720 (64.7)</td>
                           
                           <td class="center-aligned">1315 (63.3)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Any other lipid‐lowering therapy, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">127 (22.8)</td>
                           
                           <td class="center-aligned">231 (23.2)</td>
                           
                           <td class="center-aligned">443 (33.2)</td>
                           
                           <td class="center-aligned">770 (32.8)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Anti‐hyperglycaemic agent, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">459 (82.3)</td>
                           
                           <td class="center-aligned">828 (83.1)</td>
                           
                           <td class="center-aligned">0</td>
                           
                           <td class="center-aligned">0</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Injectable anti‐hyperglycaemic, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">132 (23.7)</td>
                           
                           <td class="center-aligned">265 (26.6)</td>
                           
                           <td class="center-aligned">0</td>
                           
                           <td class="center-aligned">0</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Insulin, <i>n</i> (%)
                           </td>
                           
                           <td class="center-aligned">123 (22.0)</td>
                           
                           <td class="center-aligned">242 (24.3)</td>
                           
                           <td class="center-aligned">0</td>
                           
                           <td class="center-aligned">0</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">LDL cholesterol</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/l</td>
                           
                           <td class="center-aligned">3.0 (1.1)</td>
                           
                           <td class="center-aligned">3.0 (1.0)</td>
                           
                           <td class="center-aligned">3.4 (1.3)</td>
                           
                           <td class="center-aligned">3.4 (1.3)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mg/dl</td>
                           
                           <td class="center-aligned">115.9 (41.8)</td>
                           
                           <td class="center-aligned">115.7 (37.9)</td>
                           
                           <td class="center-aligned">130.6 (50.3)</td>
                           
                           <td class="center-aligned">130.0 (49.8)</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">Non‐HDL cholesterol</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/l</td>
                           
                           <td class="center-aligned">3.8 (1.2)</td>
                           
                           <td class="center-aligned">3.9 (1.1)</td>
                           
                           <td class="center-aligned">4.1 (1.4)</td>
                           
                           <td class="center-aligned">4.1 (1.4)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mg/dl</td>
                           
                           <td class="center-aligned">148.3 (47.9)</td>
                           
                           <td class="center-aligned">149.3 (43.9)</td>
                           
                           <td class="center-aligned">159.0 (55.3)</td>
                           
                           <td class="center-aligned">157.5 (53.5)</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">Triglycerides, median (Q1:Q3)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/l</td>
                           
                           <td class="center-aligned">1.6 (1.2:2.3)</td>
                           
                           <td class="center-aligned">1.7 (1.2:2.3)</td>
                           
                           <td class="center-aligned">1.4 (1.0:2.0)</td>
                           
                           <td class="center-aligned">1.4 (1.0:1.9)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mg/dl</td>
                           
                           <td class="center-aligned">144.0 (107.1:201.0)</td>
                           
                           <td class="center-aligned">147.0 (108.0:207.0)</td>
                           
                           <td class="center-aligned">122.1 (89.4:175.0)</td>
                           
                           <td class="center-aligned">120.0 (87.6:167.3)</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">HDL cholesterol</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/l</td>
                           
                           <td class="center-aligned">1.2 (0.3)</td>
                           
                           <td class="center-aligned">1.2 (0.3)</td>
                           
                           <td class="center-aligned">1.3 (0.4)</td>
                           
                           <td class="center-aligned">1.3 (0.4)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mg/dl</td>
                           
                           <td class="center-aligned">47.4 (12.3)</td>
                           
                           <td class="center-aligned">46.9 (11.9)</td>
                           
                           <td class="center-aligned">51.0 (13.8)</td>
                           
                           <td class="center-aligned">51.3 (14.2)</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">FPG</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/l</td>
                           
                           <td class="center-aligned">7.5 (2.4)</td>
                           
                           <td class="center-aligned">7.5 (2.3)</td>
                           
                           <td class="center-aligned">5.5 (0.8)</td>
                           
                           <td class="center-aligned">5.5 (0.7)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mg/dl</td>
                           
                           <td class="center-aligned">135.9 (43.9)</td>
                           
                           <td class="center-aligned">135.1 (41.3)</td>
                           
                           <td class="center-aligned">98.8 (13.8)</td>
                           
                           <td class="center-aligned">99.2 (13.1)</td>
                           
                        </tr>
<tr>
<td colspan="5" class="left-aligned">HbA<sub>1c</sub>
</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">mmol/mol</td>
                           
                           <td class="center-aligned">52 (12)</td>
                           
                           <td class="center-aligned">52 (11)</td>
                           
                           <td class="center-aligned">38 (5)</td>
                           
                           <td class="center-aligned">38 (4)</td>
                           
                        </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">%</td>
                           
                           <td class="center-aligned">6.9 (1.1)</td>
                           
                           <td class="center-aligned">6.9 (1.1)</td>
                           
                           <td class="center-aligned">5.7 (0.4)</td>
                           
                           <td class="center-aligned">5.7 (0.4)</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Duration of diabetes, years</td>
                           
                           <td class="center-aligned">9.1 (8.7)</td>
                           
                           <td class="center-aligned">9.3 (8.4)</td>
                           
                           <td class="center-aligned">0</td>
                           
                           <td class="center-aligned">0</td>
                           
                        </tr>
<tr>
<td class="right-bordered-cell left-aligned">Duration of total exposure to study treatment, weeks</td>
                           
                           <td class="center-aligned">58.4 (31.1)</td>
                           
                           <td class="center-aligned">62.4 (29.2)</td>
                           
                           <td class="center-aligned">58.4 (31.3)</td>
                           
                           <td class="center-aligned">63.6 (30.0)</td>
                           
                        </tr>
</tbody>
</table>
</div>
               
               
               
               <div class="article-section__table-footnotes">
                  <ul>
<li id="dme13817-note-0002">
                        FPG, fasting plasma glucose.
                        
                     </li>
                     <li id="dme13817-note-0003">
                        Values are mean (<span class="smallCaps">sd</span>), unless otherwise specified.
                        
                     </li>
                     <li id="dme13817-note-0004">
                        *Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. <sup>†</sup><i>n</i>/<i>N</i> = number of people in phase 3 studies only. <sup>‡</sup>High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
                        
                     </li>
                     <li id="dme13817-note-0005">
                        Study references: phase 2 trials [DFI111565 
(NCT01288443), DFI11566 (NCT01288469), CL‐1003 (NCT01266876), DFI12361 
(NCT01812707)]; phase 3 trials [LONG TERM (NCT01507831), HIGH FH 
(NCT01617655), COMBO I (NCT01644175), FH I (NCT01623115), FH II 
(NCT01709500), COMBO II (NCT01644188), OPTIONS I (NCT01730040), OPTIONS 
II (NCT01730053), MONO (NCT01644474), and ALTERNATIVE (NCT01709513)].
                        
                     </li>
                  </ul>
</div>
               <div class="article-section__table-source"></div>
            </div>